Rapport Therapeutics RAPP
Rapport Therapeutics, Inc. · Nasdaq · Pharmaceutical Preparations
$22.50-18.30%close on Oct. 28, 2026 · volume 5.9M · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 23, 2026 | Ramiro Sanchez director | Bought | 3,600 | $27.35 | $98,478 |
| Oct. 22, 2026 | Paul M. Silva director · indirect | Bought | 3,680 | $27.08 | $99,636 |
| Oct. 22, 2026 | Wendy B. Young director | Bought | 3,789 | $26.39 | $99,992 |
| Oct. 22, 2026 | Steven M. Paul director · indirect | Bought | 35,714 | $27.28 | $974,278 |
| Oct. 22, 2026 | John Maraganore director · indirect | Bought | 9,411 | $26.45 $26.38-$26.92 | $248,891 |
| Oct. 21, 2026 | Abraham Ceesay Chief Executive Officer, director | Sold 10b5-1 plan | 2,210 | $29.16 | $64,448 |
| Oct. 21, 2026 | Troy A. Ignelzi Chief Financial Officer | Bought | 5,500 | $26.10 | $143,550 |
| Oct. 7, 2026 | Abraham Ceesay Chief Executive Officer, director | Sold 10b5-1 plan | 1,147 | $30.66 | $35,167 |
| Oct. 6, 2026 | Abraham Ceesay Chief Executive Officer, director | Sold 10b5-1 plan | 3,375 | $32.03 | $108,106 |
| Sept. 30, 2026 | Cheryl Gault Chief Operating Officer | Sold 10b5-1 plan | 10,000 | $33.19 $33.04-$33.76 | $331,856 |
| Sept. 23, 2026 | Abraham Ceesay Chief Executive Officer, director | Sold 10b5-1 plan | 2,210 | $39.17 $39.05-$41.05 | $86,565 |
| Sept. 8, 2026 | Abraham Ceesay Chief Executive Officer, director | Sold 10b5-1 plan | 8,210 | $45.61 $45.56-$46.01 | $374,498 |
Latest 12 of 19. Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.